Main Article Content
prognostic factors, clear cell carcinoma of endometrium, endometrial cancer; stage, survival, recurrence.
Background and aim of the work: The purpose of this study was to evaluate the clinical and pathologic prognostic factors associated with survival in patients with clear cell carcinoma (CCC) of the endometrium. Methods: A retrospective review of fifty-five patients with endometrial clear cell carcinoma were collected. Results: The median overall and disease-free survivals were 40 and 20 months, respectively. A univariate analysis was performed with respect to stage of disease, age, lymph nodes status, myometrium invasion, lymph vascular space invasion and adjuvant therapy. Stage was found to be the only important prognostic factor related to survival. In fact, early stage had a median survival of 77 months compared to 34 months in the advanced disease (p<0.04). These differences remained significant after adjusting for single stage (stage III versus IV). Conclusions: Endometrial CCC is a rare histotype. Advanced stage disease is considered a poor prognostic factor. Recurrences are high even in early stage. Randomized clinical trials are needed.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7.
3. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
4. Lax S. [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology]. Pathologe. 2011;32 Suppl 2:255-64.
5. Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol. 2006;30(12):1519-30.
6. Abdulfatah E, Sakr S, Thomas S, Al-Wahab Z, Mutch DG, Dowdy S, et al. Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases. Int J Gynecol Cancer. 2017;27(8):1714-21.
7. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642-6.
8. Abeler VM, Vergote IB, Kjorstad KE, Trope CG. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996;78(8):1740-7.
9. Gadducci A, Cosio S, Spirito N, Cionini L. Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res. 2010;30(4):1327-34.
10. Vance S, Yechieli R, Cogan C, Hanna R, Munkarah A, Elshaikh MA. The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma. Gynecol Oncol. 2012;126(1):16-9.
11. Varughese J, Hui P, Lu L, Yu H, Schwartz PE. Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression. J Oncol. 2011;2011:628084.
12. Vandenput I, Vanhove T, Calster BV, Gorp TV, Moerman P, Verbist G, et al. The use of lymph vessel markers to predict endometrial cancer outcome. Int J Gynecol Cancer. 2010;20(3):363-7.
13. Sari ME, Meydanli MM, Turkmen O, Comert GK, Turan AT, Karalok A, et al. Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study. J Gynecol Oncol. 2017;28(4):e49.
14. Mahdi H, Lockhart D, Moselmi-Kebria M. Prognostic impact of lymphadenectomy in uterine clear cell carcinoma. J Gynecol Oncol. 2015;26(2):134-40.
15. Thomas M, Mariani A, Wright JD, Madarek EO, Powell MA, Mutch DG, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol. 2008;108(2):293-7.
16. Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005;23(16):3668-75.
17. Fadare O, Zheng W, Crispens MA, Jones HW, Khabele D, Gwin K, et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am J Cancer Res. 2013;3(1):70-95.
18. Cetinkaya N, Selcuk I, Ozdal B, Meydanli MM, Gungor T. Prognostic factors in endometrial clear cell carcinoma. Arch Gynecol Obstet. 2017;295(1):189-95.
19. Olawaiye AB, Boruta DM, 2nd. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;113(2):277-83.
20. Kwon JS, Abrams J, Sugimoto A, Carey MS. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? Int J Gynecol Cancer. 2008;18(4):820-4.
21. Sovak MA, Hensley ML, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol Oncol. 2006;103(2):451-7.
22. Foerster R, Kluck R, Rief H, Rieken S, Debus J, Lindel K. Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy. Radiat Oncol. 2014;9:141.
23. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;55(5):1272-6.